Andrew J. Fromkin

Andrew J. Fromkin, listed as senior executive, appears in our data through filings on Immunovant, Inc. shares, published by SEC (Form 4). The record holds 16 filings, for trades running from 10 August 2021 to 28 May 2026.

Both buying and selling appear: 1 purchase worth €37k, against 5 sales worth €7.1M. Taken together, the sales exceed the purchases by €7.0M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 6 share grants and 4 option exercises. In 2026 alone, the filings show no purchases and 2 sales.

The newest entry dates from 29 May 2026: an option exercise of €136k, in Immunovant, Inc. The last insider purchase was made public on 11 August 2021, 1,894 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.